Long-term follow-up of RCT: Nivolumab plus chemotherapy or ipilimumab in gastro-esophageal cancer.

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer – Nature

Original Study: RCT: First-line nivolumab plus chemotherapy vs. chemotherapy alone for advanced gastric, gastro-esophageal junction, and esophageal adenocarcinoma.

Commentary on Twitter

New data from CheckMate 649 confirm that the OS benefit of nivolumab added to chemotherapy for advanced-stage gastroesophageal adenocarcinoma persists beyond 24 mo (HR 0.79; 95% CI 0.71-0.88); however, nivo+ipi did not improve OS vs chemotherapy alone: https://t.co/2Pom4zD7oX

— NatureRevClinOncol (@NatRevClinOncol) March 25, 2022